Second look, in primary site recurrence or second primary for T1 and T2 glottic cancer treated by CO2 laser

International Journal of Otorhinolaryngology and Head and Neck Surgery Pub Date : 2024-01-25 DOI:10.18203/issn.2454-5929.ijohns20240050

K. Luna-Ortiz, V. Villavicencio-Valencia, Zelik Luna-Peteuil, Diana Villavicencio-Valencia, D. García-Ortega, Philippe Pasche

{"title":"Second look, in primary site recurrence or second primary for T1 and T2 glottic cancer treated by CO2 laser","authors":"K. Luna-Ortiz, V. Villavicencio-Valencia, Zelik Luna-Peteuil, Diana Villavicencio-Valencia, D. García-Ortega, Philippe Pasche","doi":"10.18203/issn.2454-5929.ijohns20240050","DOIUrl":null,"url":null,"abstract":"Background: Aim was to analyze the impact of second-look surgery in the surveillance of T1 and T2 glottic cancer treated with CO2 laser.\nMethods: Retrospective review of 98 patients treated between February 2005 and December 2022.\nResults: Among 98 patients with early glottic cancer (T1/T2), 56 (57%) with suspected recurrence underwent a second-look surgery. Of all patients, 38 (38.77%) recurred 6 months after initial resection, 17 of which (45%) had a lesion in a different site from the primary. Of these 38 patients, 22 (58%) underwent laser surgery once, 12 (32%) underwent laser surgery twice, and 4 (10%) underwent laser surgery on three occasions during follow-up. The 5-year disease-free survival, 5-year survival, and larynx preservation rates were, respectively, 54%, 82%, and 90.8%. \nConclusions: Transoral resection is currently the first treatment option for early-stage glottic carcinoma because diagnosis and prompt treatment can be provided on an outpatient basis at the same time.","PeriodicalId":14350,"journal":{"name":"International Journal of Otorhinolaryngology and Head and Neck Surgery","volume":"25 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Otorhinolaryngology and Head and Neck Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2454-5929.ijohns20240050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Aim was to analyze the impact of second-look surgery in the surveillance of T1 and T2 glottic cancer treated with CO2 laser. Methods: Retrospective review of 98 patients treated between February 2005 and December 2022. Results: Among 98 patients with early glottic cancer (T1/T2), 56 (57%) with suspected recurrence underwent a second-look surgery. Of all patients, 38 (38.77%) recurred 6 months after initial resection, 17 of which (45%) had a lesion in a different site from the primary. Of these 38 patients, 22 (58%) underwent laser surgery once, 12 (32%) underwent laser surgery twice, and 4 (10%) underwent laser surgery on three occasions during follow-up. The 5-year disease-free survival, 5-year survival, and larynx preservation rates were, respectively, 54%, 82%, and 90.8%. Conclusions: Transoral resection is currently the first treatment option for early-stage glottic carcinoma because diagnosis and prompt treatment can be provided on an outpatient basis at the same time.

查看原文本刊更多论文

通过二氧化碳激光治疗 T1 和 T2 声门癌的原发部位复发或第二原发时的第二次观察

背景目的：分析二诊手术对CO2激光治疗T1和T2声门癌监测的影响：方法：回顾性分析2005年2月至2022年12月期间接受治疗的98例患者：在98例早期声门癌（T1/T2）患者中，有56例（57%）疑似复发，接受了二次复查手术。在所有患者中，38例（38.77%）在初次切除术后6个月复发，其中17例（45%）的病变部位与原发部位不同。在这38名患者中，22人（58%）接受过一次激光手术，12人（32%）接受过两次激光手术，4人（10%）在随访期间接受过三次激光手术。5年无病生存率、5年生存率和喉部保留率分别为54%、82%和90.8%。结论：经口切除术是目前治疗喉癌的首选方法：经口切除术是目前早期声门癌的首选治疗方法，因为在门诊就能同时进行诊断和及时治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Otorhinolaryngology and Head and Neck Surgery

自引率

0.00%

发文量